Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tom Ferguson

Showing results (11-20 of 15) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 15 results.
Clinical Genitourinary Cancer|June 23, 2026
Pembrolizumab and Denosumab in Clear-Cell Renal-Cell CarcinomaCarole A Harris, Danka S Zebic, Michelle F Morris, et al.
BJU International|November 21, 2023
A phase II trial of nivolumab followed by ipilimumab and nivolumab in advanced non-clear-cell renal cell carcinomaCiara Conduit, Ian D Davis, Jeffrey C Goh, et al.
The New England Journal of Medicine|July 1, 2026
Adjuvant Pembrolizumab plus Belzutifan for Renal-Cell CarcinomaToni K Choueiri, Robert J Motzer, Jose A Karam, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 24, 2016
SIRFLOX: Randomized Phase III Trial Comparing First-Line mFOLFOX6 (Plus or Minus Bevacizumab) Versus mFOLFOX6 (Plus or Minus Bevacizumab) Plus Selective Internal Radiation Therapy in Patients With Metastatic Colorectal CancerGuy A van Hazel, Volker Heinemann, Navesh K Sharma, et al.
The New England Journal of Medicine|April 17, 2024
Overall Survival with Adjuvant Pembrolizumab in Renal-Cell CarcinomaToni K Choueiri, Piotr Tomczak, Se Hoon Park, et al.
Pageof 2

Showing results (11-20 of 15) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 15 results.
Clinical Genitourinary Cancer|June 23, 2026
Pembrolizumab and Denosumab in Clear-Cell Renal-Cell CarcinomaCarole A Harris, Danka S Zebic, Michelle F Morris, et al.
BJU International|November 21, 2023
A phase II trial of nivolumab followed by ipilimumab and nivolumab in advanced non-clear-cell renal cell carcinomaCiara Conduit, Ian D Davis, Jeffrey C Goh, et al.
The New England Journal of Medicine|July 1, 2026
Adjuvant Pembrolizumab plus Belzutifan for Renal-Cell CarcinomaToni K Choueiri, Robert J Motzer, Jose A Karam, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 24, 2016
SIRFLOX: Randomized Phase III Trial Comparing First-Line mFOLFOX6 (Plus or Minus Bevacizumab) Versus mFOLFOX6 (Plus or Minus Bevacizumab) Plus Selective Internal Radiation Therapy in Patients With Metastatic Colorectal CancerGuy A van Hazel, Volker Heinemann, Navesh K Sharma, et al.
The New England Journal of Medicine|April 17, 2024
Overall Survival with Adjuvant Pembrolizumab in Renal-Cell CarcinomaToni K Choueiri, Piotr Tomczak, Se Hoon Park, et al.
Pageof 2